Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD40 | P25942 | 2/20 | 0.52 |
| ▸ | CD40LG | P29965 | 2/20 | 0.52 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.47 |
| ▸ | PLK1 | P53350 | 6/20 | 0.45 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.43 |
| ▸ | PLK3 | Q9H4B4 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10035673 | 0.88 | ABCG2 (0.57) | ABCG2TRPV1SENP8SENP7SENP6 | |
| SCHEMBL10035676 | 0.77 | PLK1 (0.57) | ABCG2SENP8SENP7SENP6PLK1 | |
| SCHEMBL10035663 | 0.77 | SENP8 (0.55) | ABCG2TRPV1SENP8SENP7SENP6 | |
| SCHEMBL6362788 | 0.75 | LMNA (0.49) | CD40CD40LGGAA | |
| SCHEMBL3217784 | 0.74 | HPGD (0.54) | NPC1RAB9A | |
| SCHEMBL13599245 | 0.74 | CD40 (0.55) | CD40CD40LGABCG2TRPV1PLK1 | |
| SCHEMBL12630739 | 0.71 | CA1 (0.46) | NPC1GAARAB9A | |
| SCHEMBL13599246 | 0.71 | MMP12 (0.45) | ABCG2SENP8SENP7SENP6PLK1 | |
| SCHEMBL14539253 | 0.69 | CA1 (0.49) | NPC1RAB9A | |
| SCHEMBL14473033 | 0.69 | HDAC1 (0.68) | SENP8SENP7SENP6NPC1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110329-B2 | Charge controlling agent and toner | CANON KABUSHIKI KAISHA (JP) | 2012-02-07 | — | — | US | disclosed |
| US-20070111125-A1 | CHARGE CONTROLLING AGENT AND TONER | CANON KABUSHIKI KAISHA (JP) | 2007-05-17 | — | — | US | disclosed |
| US-20070111125-A1 | CHARGE CONTROLLING AGENT AND TONER | CANON KABUSHIKI KAISHA (JP) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111125-A1 | CHARGE CONTROLLING AGENT AND TONER | CA2, ACTR2, CA12 | CD40 4822/4885CD40LG 4877/4885ABCG2 4241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.